HomeCompareJXHGF vs JNJ

JXHGF vs JNJ: Dividend Comparison 2026

JXHGF yields 2.56% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $3.6K in total portfolio value· pulled ahead in Year 9
10 years
JXHGF
JXHGF
● Live price
2.56%
Share price
$8.99
Annual div
$0.23
5Y div CAGR
10.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.6K
Annual income
$916.58
Full JXHGF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — JXHGF vs JNJ

📍 JNJ pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJXHGFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JXHGF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JXHGF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JXHGF
Annual income on $10K today (after 15% tax)
$217.46/yr
After 10yr DRIP, annual income (after tax)
$779.09/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,206.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JXHGF + JNJ for your $10,000?

JXHGF: 50%JNJ: 50%
100% JNJ50/50100% JXHGF
Portfolio after 10yr
$28.5K
Annual income
$2,802.99/yr
Blended yield
9.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

JXHGF
No analyst data
Altman Z
2.2
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JXHGF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJXHGFJNJ
Forward yield2.56%2.13%
Annual dividend / share$0.23$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR10.6%28%
Portfolio after 10y$26.6K$30.3K
Annual income after 10y$916.58$4,689.40
Total dividends collected$5.4K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JXHGF vs JNJ ($10,000, DRIP)

YearJXHGF PortfolioJXHGF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,983$282.96$10,592$272.30+$391.00JXHGF
2$12,073$321.23$11,289$357.73+$784.00JXHGF
3$13,283$364.99$12,123$472.89+$1.2KJXHGF
4$14,628$415.08$13,141$629.86+$1.5KJXHGF
5$16,124$472.49$14,408$846.81+$1.7KJXHGF
6$17,792$538.35$16,021$1,151.60+$1.8KJXHGF
7$19,651$613.99$18,122$1,588.22+$1.5KJXHGF
8$21,727$700.98$20,930$2,228.20+$797.00JXHGF
9← crossover$24,050$801.13$24,792$3,191.91$742.00JNJ
10$26,650$916.58$30,274$4,689.40$3.6KJNJ

JXHGF vs JNJ: Complete Analysis 2026

JXHGFStock

ENEOS Holdings, Inc., through its subsidiaries, engages in the energy, oil and natural gas exploration and production (E&P), and metals businesses Japan, China, and internationally. The company operates through Energy, Oil and Natural Gas E&P, Metals, and Other segments. It manufactures and sells petroleum products, including gasoline, kerosene, lubricants, etc., as well as petrochemicals; and offers crude oil, natural gas, and copper concentrates. In addition, the company offers non-ferrous metal products, including electrolytic coppers, functional materials, and thin-film materials. Further, the company develops and explores non-ferrous metal resources and products; recycles industrial waste treatment, titanium, and electric wires. Additionally, the company offers copper foils, precision rolled, and precision-fabricated products. Furthermore, it engages in the asphalt paving, civil engineering, construction, land transportation, and real estate leasing business. It is engaged in the sales of mineral resources; and researching, studying, evaluating, designing and planning, and consulting services. ENEOS Holdings, Inc. was founded in 1888 and is headquartered in Tokyo, Japan.

Full JXHGF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this JXHGF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JXHGF vs SCHDJXHGF vs JEPIJXHGF vs OJXHGF vs KOJXHGF vs MAINJXHGF vs ABBVJXHGF vs MRKJXHGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.